EMPLOYMENT AGREEMENTEmployment Agreement • March 15th, 2022 • Adicet Bio, Inc. • Pharmaceutical preparations • California
Contract Type FiledMarch 15th, 2022 Company Industry JurisdictionThis Employment Agreement (“Agreement”) is made between Adicet Bio, Inc., a Delaware corporation (the “Company”), and _____________________ (the “Executive”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • March 8th, 2022 • Magenta Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
Contract Type FiledMarch 8th, 2022 Company Industry JurisdictionThis Amended and Restated Employment Agreement (“Agreement”) is made by and between Magenta Therapeutics, Inc., a Delaware corporation (the “Company”), and Jason Gardner, D.Phil. (the “Executive”) and is effective as March 3, 2022.
EMPLOYMENT AGREEMENTEmployment Agreement • September 16th, 2021 • Thayer Ventures Acquisition Corp • Blank checks • Colorado
Contract Type FiledSeptember 16th, 2021 Company Industry JurisdictionThis Employment Agreement (“Agreement”) is made between Inspirato LLC (the “Company”), and Brad Handler (the “Executive”) and is effective as of consummation of the transactions contemplated by the Business Combination Agreement (the “BCA”), dated as of June 30, 2021 to which the Company is a party (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • September 16th, 2021 • Thayer Ventures Acquisition Corp • Blank checks • Colorado
Contract Type FiledSeptember 16th, 2021 Company Industry JurisdictionThis Employment Agreement (“Agreement”) is made between Inspirato LLC (the “Company”), and Brent Handler (the “Executive”) and is effective as of consummation of the transactions contemplated by the Business Combination Agreement (the “BCA”), dated as of June 30, 2021 to which the Company is a party (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • July 6th, 2020 • Unum Therapeutics Inc. • Pharmaceutical preparations • Massachusetts
Contract Type FiledJuly 6th, 2020 Company Industry JurisdictionThis Employment Agreement (“Agreement”) is made between Unum Therapeutics Inc., a Delaware corporation (the “Company”) and John L. Green (the “Executive”).
EX-10.1 2 d676576dex101.htm EX-10.1 Execution Version AVROBIO, INC. EMPLOYMENT AGREEMENTEmployment Agreement • May 5th, 2020 • Massachusetts
Contract Type FiledMay 5th, 2020 JurisdictionThis Employment Agreement (“Agreement”) is made as of the 17th day of December, 2018, between AVROBIO, Inc., a Delaware corporation (the “Company”), and Erik Ostrowski (the “Executive”).
AVROBIO, INC. EMPLOYMENT AGREEMENTEmployment Agreement • December 21st, 2018 • AVROBIO, Inc. • Biological products, (no disgnostic substances) • Massachusetts
Contract Type FiledDecember 21st, 2018 Company Industry JurisdictionThis Employment Agreement (“Agreement”) is made as of the 17th day of December, 2018, between AVROBIO, Inc., a Delaware corporation (the “Company”), and Erik Ostrowski (the “Executive”).
SCPHARMACEUTICALS INC. EMPLOYMENT AGREEMENTEmployment Agreement • November 7th, 2017 • scPharmaceuticals Inc. • Pharmaceutical preparations • Massachusetts
Contract Type FiledNovember 7th, 2017 Company Industry JurisdictionThis Employment Agreement (“Agreement”) is made as of the day of , 2017, between scPharmaceuticals Inc., a Delaware corporation (the “Company”), and John H. Tucker (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”).
SCPHARMACEUTICALS INC. EMPLOYMENT AGREEMENTEmployment Agreement • November 7th, 2017 • scPharmaceuticals Inc. • Pharmaceutical preparations • Massachusetts
Contract Type FiledNovember 7th, 2017 Company Industry JurisdictionThis Employment Agreement (“Agreement”) is made as of the day of , 2017, between scPharmaceuticals Inc., a Delaware corporation (the “Company”), and Abraham Ceesay (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”).
SCPHARMACEUTICALS INC. EMPLOYMENT AGREEMENTEmployment Agreement • November 7th, 2017 • scPharmaceuticals Inc. • Pharmaceutical preparations • Massachusetts
Contract Type FiledNovember 7th, 2017 Company Industry JurisdictionThis Employment Agreement (“Agreement”) is made as of the day of , 2017, between scPharmaceuticals Inc., a Delaware corporation (the “Company”), and Troy Ignelzi (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”).
AERPIO PHARMACEUTICALS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • October 10th, 2017 • Aerpio Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
Contract Type FiledOctober 10th, 2017 Company Industry JurisdictionThis Employment Agreement (“Agreement”) is made between Aerpio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Stephen Hoffman (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • October 17th, 2016 • Ra Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
Contract Type FiledOctober 17th, 2016 Company Industry JurisdictionThis Employment Agreement (“Agreement”) is made as of the [ ] day of [ ], 2016 between Ra Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Ramin Farzaneh-Far (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • October 17th, 2016 • Ra Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
Contract Type FiledOctober 17th, 2016 Company Industry JurisdictionThis Employment Agreement (“Agreement”) is made as of the [ ] day of [ ], 2016, between Ra Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and David Lubner (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”).